'Naturally, the conversation touched on the major contract that Unilife CEO Alan Shortall alluded to on the company's Q3 2013 earnings call. Stephen Allan stated that although this particular contract is taking longer to sign than expected, it is due to the formalities needed for approval within that pharmaceutical company, and should not be construed as a commentary on the potential for the Unifill platform, which is the focus of this particular contract. We expect an update on this when Unilife reports Q4 2013 results, for analysts covering the company will certainly want more detail on the status of this deal, if it is not announced by the time that Unilife reports its results. However, this one contract is unlikely to represent the limit of Unilife's potential..............
UNS Price at posting:
59.5¢ Sentiment: Hold Disclosure: Held